Two drugs better than one in relapsed indolent lymphoma

The addition of lenalidomide to rituximab extends progression-free survival by two years, US study shows

Patients with relapsed or refractory indolent non-Hodgkin lymphoma enjoy two years of progression-free survival when lenalidomide is added to routine rituximab teatment, a study shows.